Skip to main content

Table 1 Demographic variables, psychiatric and HIV disease characteristics of the study participants (N = 97)

From: Association between Veterans Aging Cohort Study (VACS) index and neurocognitive function among people living with HIV–a cross sectional study in coastal South India

Characteristics

All

Neurocognitively unimpaired N (%)

Neurocognitively impaired N (%)

p value

Demographics

Age [years, M (S.D.)]a

43.6 (09.6)

0.04

Genderb

 Male [N (%)]

72 (74.2)

23 (31.9)

49 (68.1)

0.26

 Female [N (%)]

25 (25.8)

05 (20.0)

20 (80.0)

Socioeconomic status [Kuppuswamy Scale] [N (%)]c

 Lower

02 (02.1)

00 (00.0)

02 (100.0)

0.21

 Upper lower

70 (72.2)

18 (25.7)

52 (74.3)

 Lower middle

18 (18.6)

07 (38.9)

11 (61.1)

 Upper middle

07 (07.2)

03 (42.9)

04 (57.1)

 Upper

00 (00.0)

00 (00.0)

00 (00.0)

No. of years of education [M (S.D.)]a

10.9 (04.4)

0.68

Psychiatric characteristics [N (%)]

 Mood symptoms (Based on Beck’s Depression Inventory)c

  Normal

89 (91.8)

49 (55.1)

40 (44.9)

0.78

  Mild mood disturbances

08 (08.2)

05 (62.5)

03 (37.5)

HIV disease characteristics

 CD4 cell count [M (S.D.)]a

466.6 (189.2)

0.11

 Nadir CD4 cell count [M (S.D.)]a

185 (54.1)

0.22

Diagnosed with AIDs [N (%)]c

 

 

 Yes

13 (13.4)

00 (00.0)

13 (100.0)

0.98

 No

84 (86.6)

28 (33.3)

56 (66.7)

Time since HIV diagnosis [M (S.D.)]a

08.4 (02.1)

-

-

0.67

ART statusc

 On ART [N (%)]

95 (97.9)

27 (28.4)

68 (71.6)

0.58

 Not on ART [N (%)]

02 (02.1)

01 (50.0)

01 (50.0)

Duration of ART (years) [M (S.D.)]a

2.6 (1.9)

0.94

Efavirenz-based treatment regimenb

    

N (%) On Efavirenz

49 (50.5)

14 (28.6)

35 (71.4)

0.79

N (%) Not on Efavirenz

46 (49.5)

12 (26.1)

34 (73.9)

ART regimen [N (%)]

 TDF + 3TC + EFV

49 (50.5)

 

 AZT + 3TC + NVP

39 (40.2)

 

 AZT + 3TC + LPV/r

02 (02.1)

 

 AZT + 3TC + ABC

02 (02.1)

 

 TDF + 3TC + ABC

02 (02.1)

 

 TDF + 3TC + LPV/r

01 (01.0)

 
  1. Statistical tests used are as follows
  2. TDF Tenofovir, 3TC Lamivudine, EFV Efavirenz, AZT Zidovudine, NVP Nevirapine, LPV/r Lopinavir-ritonavir, ABC Abacavir
  3. aIndependent sample t test, bChi Square Test, cFischer’s exact test